LLY
Eli Lilly and Company
LLY has the edge over MRVL overall, supported by stronger valuation and lower modeled downside.
MRVL
Marvell Technology, Inc.
MRVL offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MRVL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Healthy |
MRVL's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over MRVL in the historical PE scenario, which offers more potential upside but is not a forecast.
MRVL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $51.02 | -69% |
| Fair | 25x | $75.19 | -54% |
| Forward | 25x | $164 | — |
| Current | 54x | $164 | — |
| Expensive | 71x | $215 | +31% |
Historical ranges are pointers, not guarantees.
MRVL's PE is in its expensive range at 54x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MRVL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for MRVL, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MRVL on earnings, with more consistent year-over-year improvement.
MRVL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.51 | +116% |
| Q3 2026 | $3.02 | +$3.15 |
| Q2 2026 | $2.91 | +$3.48 |
| Q1 2026 | $3.07 | +$4.09 |
| Q4 2025 | $2.85 | +$4.55 |
| Q3 2025 | -$0.13 | +$0.98 |
| Q2 2025 | -$0.57 | +$0.56 |
| Q1 2025 | -$1.02 | +$0.06 |
| Q4 2024 | -$1.70 | -$1.05 |
MRVL has returned to profit: it earned $3.02 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MRVL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MRVL on profitability, with a higher operating margin.
MRVL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7B | +37% |
| Q2 2026 | $2.4B | +28% |
| Q1 2026 | $2.2B | +22% |
| Q4 2025 | $2.1B | +37% |
| Q3 2025 | $2B | +58% |
| Q2 2025 | $1.9B | +63% |
| Q1 2025 | $1.8B | +27% |
| Q4 2024 | $1.5B | +6.9% |
MRVL's revenue has grown year over year for eight quarters in a row: $2.7B last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +2.3 points |
| Q2 2026 | 14% | -0.2 points |
| Q1 2026 | 18% | +5.3 points |
| Q4 2025 | 17% | +64 points |
| Q3 2025 | 14% | +22 points |
| Q2 2025 | 14% | +27 points |
| Q1 2025 | 13% | +15 points |
| Q4 2024 | -46% | -36 points |
MRVL's operating margin was 17% last quarter, up 2.3 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MRVL on cash flow, with more consistent year-over-year improvement.
MRVL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $478.8M | +16% |
| Q2 2026 | $483.1M | +126% |
| Q1 2026 | $259.4M | -42% |
| Q4 2025 | $508.8M | +10% |
| Q3 2025 | $414.1M | +60% |
| Q2 2025 | $214.1M | -8.1% |
| Q1 2025 | $444.1M | -6.6% |
| Q4 2024 | $461.3M | +2.8% |
MRVL generated $1.7B in free cash flow over the past year, up 13% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MRVL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MRVL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +27.9M shares |
| 1 year | +5.8% | +50.8M shares |
| 3 years | +7% | +60.3M shares |
| 5 years | +12% | +100M shares |
| Available history | +38% | +253M shares |
MRVL has 921M diluted shares, up 5.8% from a year ago, despite $1.9B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $200M |
| Q2 2026 | $200M |
| Q1 2026 | $200.1M |
| Q4 2025 | $1.3B |
| Q3 2025 | $200M |
| Q2 2025 | $340M |
| Q1 2025 | $200M |
| Q4 2024 | $200M |
MRVL spent $1.9B buying back its own shares over the past year, up 102% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MRVL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 1.5x | Healthy |
| Q4 2020 | 0.5x | Very low |
| Q3 2020 | 0.6x | Very low |
| Q2 2020 | 0.7x | Very low |
| Q1 2020 | 0.7x | Very low |
| Q4 2019 | 5.3x | High |
MRVL's net debt is about 1.5 years of its operating earnings (EBITDA), up from less than a year a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MRVL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 16.1 | Oversold |
MRVL's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over MRVL on valuation relative to its sector.
MRVL PE vs Technology Sector
| Metric | MRVL | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 28x | 95% above |
| PE % | 75 | 35 | 40 pts above |
MRVL is trading at 54x earnings, a 95% premium to the Technology sector's median of 28x.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MRVL on trend strength, trading above more of its moving averages.
MRVL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.0 | 26% below |
| 20 week MA | $220.9 | 26% below |
| 50 week MA | $168.8 | 2.5% below |
| 100 week MA | $124.8 | 32% above |
| 200 week MA | $93.8 | 75% above |
MRVL has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 75% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
MRVL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $47.1 | +76% |
| 2021 | $47.1 | $87.7 | +86% |
| 2022 | $87.7 | $37.2 | -58% |
| 2023 | $37.2 | $60.3 | +62% |
| 2024 | $60.3 | $113.6 | +88% |
| 2025 | $113.6 | $86.3 | -24% |
| 2026 YTD | $86.3 | $164.5 | +90% |
MRVL has the edge over LLY on returns for 2026, with the stronger performance.